Zeitschrift: Bulletin der Schweizerischen Akademie der Medizinischen

Wissenschaften = Bulletin de l'Académie suisse des sciences

médicales = Bollettino dell' Accademia svizzera delle scienze mediche

Herausgeber: Schweizerische Akademie der Medizinischen Wissenschaften

Band: 25 (1969)

Artikel: The use of Ro 4-8347 in amenorrhea an anovulation

Autor: Polishuk, W.Z. / Schechter, A. / Kozminski, T.

DOI: https://doi.org/10.5169/seals-307803

Nutzungsbedingungen

Die ETH-Bibliothek ist die Anbieterin der digitalisierten Zeitschriften auf E-Periodica. Sie besitzt keine Urheberrechte an den Zeitschriften und ist nicht verantwortlich für deren Inhalte. Die Rechte liegen in der Regel bei den Herausgebern beziehungsweise den externen Rechteinhabern. Das Veröffentlichen von Bildern in Print- und Online-Publikationen sowie auf Social Media-Kanälen oder Webseiten ist nur mit vorheriger Genehmigung der Rechteinhaber erlaubt. Mehr erfahren

Conditions d'utilisation

L'ETH Library est le fournisseur des revues numérisées. Elle ne détient aucun droit d'auteur sur les revues et n'est pas responsable de leur contenu. En règle générale, les droits sont détenus par les éditeurs ou les détenteurs de droits externes. La reproduction d'images dans des publications imprimées ou en ligne ainsi que sur des canaux de médias sociaux ou des sites web n'est autorisée qu'avec l'accord préalable des détenteurs des droits. En savoir plus

Terms of use

The ETH Library is the provider of the digitised journals. It does not own any copyrights to the journals and is not responsible for their content. The rights usually lie with the publishers or the external rights holders. Publishing images in print and online publications, as well as on social media channels or websites, is only permitted with the prior consent of the rights holders. Find out more

Download PDF: 26.11.2025

ETH-Bibliothek Zürich, E-Periodica, https://www.e-periodica.ch

Department of Obstetrics and Gynecology, Hadassah University Hospital, Jerusalem

The Use of Ro 4-8347 in Amenorrhea and Anovulation

W. Z. Polishuk, A. Schechter and T. Kozminski

The new progestational agent Ro 4-8347 was found to have two main properties: a) a strong progestational effect primarily on the endometrium and b) a stimulating effect on gonadotrophin secretions. These two properties served as a basis for the clinical application of Ro 4-8347 in 82 cases of amenorrhea and anovulation.

Material and method

The patients may be divided into four groups:

(*troup a*) included cases of sterility with anovulatory cyclic menstructions. In these cases, the routine sterility work-up excluded the male, tubal, peritoneal and cervical factors of sterility. Anovulation was diagnosed by vaginal smears, basal body temperature and endometrial biopsy. There were 33 such patients who received medication in 44 cycles.

Group b). Oligomenorrhea with anovulation. These were sterility patients whose only apparent reason for sterility was anovulation. Their menstrual cycles were irregular and prolonged, occurring between 5 and 12 weeks. There were 24 such cases which received 31 cycles of treatment.

Group c). Amenorrhea. These were 9 cases of primary and 6 cases of secondary amenorrhea. Except for 2 patients, they all presented some signs of ovarian function, i.e. estrogenic activity in their vaginal smear and withdrawal bleeding following the administration of progesterone.

Group d). Short-term amenorrhea. These were normally menstruating, presumably ovulating, patients who consulted us for a 4-14 days delay in their menstruation. In 10 such cases, Ro 4-8347 was given in order to induce a withdrawal bleeding and possibly ovulation.

Because of the unpredictable response to Ro 4-8347 in these cases, treatment was given according to one of several schedules. The "short course" consisted of a daily dose of 4-10 mg for a 2-6 day period. The "long course" consisted of a daily dose of 2-6 mg for periods of 10-20 days.

The response to treatment was evaluated by several criteria which included: the vaginal maturation index, basal body temperature, onset of bleeding in relations to the thermal shift, endometrial biopsy and the occurrence of pregnancy.

Results of treatment with Ro 4-8347 (Table I)

a) Anoculatory cycles. In 11 cases the "short course" of treatment was employed. Most of these cases received 8-10 mg of Ro 4-8347 daily for 5-6

Table I Cases treated with Ro 4-8347

Clinical classification	Number of cases	Number of cycles	Summary of results
1. Anovulation and amenorrhea			
a) Anovulatory cycles	33	44	24 (56%) ovulatory cycles (short course 7/11, long course 17/33)
b) Oligomenorrhea	25	31	10 (30%) ovulatory cycles (short course 3/10, long course 7/10)
			12 withdrawal bleeding
c) Amenorrhea	17	20	2 (10%) ovulatory cycles 9 withdrawal bleedings 7 increased estrone activities
d) Short-term amenorrhea	10	10	5 withdrawal bleedings
2. Normal cyclic menstruation	16	18	4 delayed ovulation 6 suppressed ovulations (BBT)
3. Meno-metrorrhagia	12	12	
4. Menopause	7	7	
5. Others	6	6	
Total	123	148	

days. The treatment was begun usually on days 10-14 of cycle, when signs of moderate to marked estrogenic activity were present. Here we relied greatly on the cervical mucus arborization as a convenient, quick, clinical test.

In 22 cases with 33 treatment cycles, the "long course" of treatment was employed. This consisted of 2–6 mg daily for 10–20 days. In 7 cases treatment began on day 5 of the cycle and lasted 20 days. Otherwise treatment started on days 10–14 of cycle and lasted for 10–14 days. The results in terms of ovulation were more or less the same in the 3 types of treatment.

"Short course": 7 out of 11 ovulated (60°_{00}) "Long course", starting on day 5: 4 out of 7 ovulated (57°_{00}) starting on day 10–14: 13 out of 26 ovulated (50°_{00})

Only one of these patients became pregnant. In the cases receiving two courses or more of treatment, ovulation did not always recur (Table II).

b) Oligomenorrhea. In 10 of the 25 cases of oligomenorrhea, there were indications that ovulation occurred following Ro 4-8347. In 7 of the 10 cases the schedule used was that of 4 5 mg daily for 10 14 days starting 10-14

days after the last menstrual period. In 12 cases of this group a withdrawal bleeding set in 3-6 days after termination of treatment. In 11 out of 12 patients who had withdrawal bleeding the schedule used was the "short course" of 10 mg for 2-5 days. One of these patients in this group became pregnant (Table III).

- c) Amenorrhea. In this group there were only 2 patients who responded to treatment by ovulating. One was a case of primary amenorrhea and one of secondary amenorrhea. In both cases the "long course" of treatment was used. In 7 cycles of treatment an increased estrogenic activity was found in vaginal smears soon after termination of Ro 4-8347 administration. In 9 of these cycles withdrawal bleeding took place.
- d) Short term amenorrhea. All these cases received a "short course" of Ro 4-8347. In 5 cases withdrawal bleeding took place 3-4 days after the last day of treatment. In 1 case, which was an early pregnancy, the patient miscarried 5 days after the last day of "treatment". This we feel, is a purely coincidental occurrence. In the other 4 cases no bleeding or ovulation took place up to 10 days following treatment. There was no correlation between the degree of estrogenic activity and the occurrence of withdrawal bleeding (Table IV).

It is noteworthy that very few patients complained of any side-effects of the drug. There were some who complained of vertigo and various gastrointestinal symptoms of mild nature.

Discussion

In summing up the effects of Ro 4-8347 medication in cases of anovulatory cycles, oligo- and amenorrhea, we should consider 3 types of reactions: 1. ovulation, 2. increased estrogenic activity, and 3. withdrawal bleeding.

Ovulation was induced by Ro 4-8347 in over 50% of cases of anovulatory cycles, in 30% of cases of oligomenorrhea and in 10% of cases of amenorrhea. Most of these ovulations followed the "long course" of treatment of 4–5 mg for 10–14 days. It is noteworthy that only in 2 cases did pregnancy follow ovulation. Some follicular activity appears to be a prerequisite for the occurrence of ovulation. In fact, in only 3 cases did ovulation follow Ro 4-8347 medication with a vaginal smear of less than 10% superficial cells.

All this points to the ability of Ro 4-8347 to induce increased gonadotrophin secretion, especially luteinizing hormone. Further evidence of this stimulatory effect may be found in the cases of amenorrhea in which an increased estrogenic activity was observed shortly after Ro 4-8347 medication. We have been employing short progesterone treatment of 100 mg intramuscularly, in cases of oligomenorrhea resulting in an occasional occurrence of ovulation. However, the desired response was not always a recurrent one, and we have no criteria for predicting the outcome of this treatment. Similar observations have been reported by other authors. The only prerequisite for a positive response has been a strong estrogenic activity as expressed by a strongly positive arborization test of cervical mucus.

Table II Ro 4-8347 in anovulation

1	No., name	Maturation Daily index dose before (mg)	Daily dose (mg)	Begins on day	During days	Vaginal smear after treatment	BBT after treatment	Blee after (dur	Bleeding after Ro 4 (during days)	Side- effects)	Ovulation
	F. R.	0/60/40	10	<u>†</u> T	ນດ	luteal effect	biphasie	ves	(6)	no	ves
	R. T.	0/72/28	4	ı~	,C	moderate estrogenie effect	biphasic	, 011	(10)	110	ves
50	N. N.		œ	10	1C		biphasic	ves	<u>න</u>	no	ves
U I	G. M.		10	14	10		biphasic	ves	(0)	ou	yes
	C. R.		10	14	10		monophasic	yes	(9)	no	no
9	G. A.		10	10	22		monophasic	ou	(10)	no	по
	Z. Y.		10	15	າດ		biphasic	ou	(10)	ou	yes
œ	G. Z.	0/32/68	10	14	10		possible rise	ou	(10)	011	yes
	A. Z.		9	10	10		monophasic	Yes	(2)	no	no
9	F. Y.	0/78/22	4	œ	9	short luteal phase	biphasic	00	(10)	по	yes
1	B. S.		œ	14	r~		monophasic	110	(10)	ou	ou
12	H. R.	0/88/12	4	13	10	delayed luteal effect	biphasie	yes	(')	no	yes
2 s	H. R.		4	6	10	delayed luteal effect	biphasic	Ves	(2)	no	yes
23	M. E.	0/62/38	4	6	10	slight estrogenic effect	monophasic	no	(10)	ou	ou
4	S.D.	0/64/36	3 0]4	10	luteal effect	biphasic	ves	(4)	ou	yes
	x x	0/86/14	9	14	10	no modified cytolysis	monophasic	ves	(3)	no	no
	H. S.	0/91/9	₩	14	10	estrogen deficiency	monophasic	yes	(9)	ou	no
17	C. M.		ତୀ	14	10		biphasic	ves	<u>(5</u>	00	yes
	B. S.	0/37/63	10	Π	01	luteal effect	biphasic	yes	(5)	no	yes
61	D. P.	0/80/20	9	14	01	no luteal effect	monophasic	yes	(4)	no	no
20	A. R.	0/48/52	4	11	10	not modified	monophasic	yes	<u> </u>	ou	ou
	y. >	11/08/0	3	1.0	10	not modified	o. o. o o o o o o o o	1.000	147	6	

					pregnancy																	
no	ou	ves	ves.	ves	pre	ou	110	no	no	ves	ves	no	So.	ves	yes	no		yes	no	yes	ves	no
ou	ou	по	ou	ou	no	ou	ou	ou	ou	no	ou	ou	no	no	no	ı.	ent	ou	ou	ou	no	ou
(4)		(5)	(+)	<u>(0</u>		<u>(8</u>	(9)	(1)	9	(4)	3	(4)	(3)	4	(4)	spotting dur-	ing treatment	(5)	<u>(0</u>	<u>(0</u>	<u> </u>	(4)
ves		ves	ves	ves		ves	ves	S.J.	ves	Ves	yes	λ es	V.CS	yes	yes	spot	ing t	ves	ves	ves	yes	sex
monophasic	monophasic	biphasic	biphasic	biphasic	biphasic	monophasic	monophasic	monophasic	monophasic	biphasic	biphasic	monophasic	biphasic	biphasic	biphasic	monophasic		biphasic	monophasic	biphasic	biphasic	monophasic
no modified eytolysis	slight luteal effect cytolysis	luteal effect cytolysis	modified estrogenic effect	luteal effect	luteal effect	not modified	not modified	not modified	slight luteal effect cytolysis	luteal effect	strong luteal effect	delayed estrogenic effect			slight luteal effect			luteal effect, delay in ovulation	no luteal effect	luteal effect	no luteal effect	slight luteal effect
01	9	01	01	0	9	<u>+</u>	+	14	14	14	14	7	14	+	50	<u>ج</u>		0 한	÷1	S.) (1	50
†	21	23	<u>::</u>	21	±	0	01	10	01	21	9	건	<u>:</u>	X	ıς	10		ĸ	17	10	10	ı:
9	10	ಸ೦	x	9	10	-,	?।	+	শ	শ	10	10	4	4	:1	Ç1		4	9	Ç1	4	4
01/06/0	0/74/26	0/72/28	0/96/4	0/57/43	0/64/36	0.80/20	0/74/26	0/85/15	0/74/26	0/73/27	0/78/22	0/60/40							0/77/23	0/93/7	0/94/6	0/94/6
W. R.	H. D.	P. A.	R. S.	B. M.	D. N.	D. N.	R. 4.	W. R.	H. D.	B. H.	C. R.	L.S.	1. 4.	H. R.	H. R.	G. Z.		T. Y.	si Si	B. M.	R. S.	P. A.
22	es es	24	255	56	57	27 a	85	9.5 a	23 23 23	56	30	31	35	12 a	12 ล	8 8		£	15 a	26 a	25 a	24 a

Table III Ro 4-8347 in oligomenorrhea

No.,	No., name	Maturation Daily index dose before (mg)	Daily dose (mg)	Begins on day	During days	During Vaginal smear after treatment days	BBT after treatment	Blec afte (dur	Bleeding after Ro 4 (during days)	Side- effects s)	Ovulation
=	M. L.	0/93/7	01		ଚା	not modified		ou		ou	
÷1	₽, Ξ	0/73/27	9		ୁ ବା	poor luteal effect		Ves	<u>(3</u>	no	
::	L. A.	0/65/35	10		61	slight luteal effect		S. A.	(9)	ou	
7	F. E.	0/78/22	10		ଦା			Yes	(4)	011	
ಣ	Z. Y.		0	=	ବା		biphasic		(15)	on	ves.
9	F. M.	0/58/42	01		m	estrogenic effect		Yes	(4)	011	
I' -	B. P.		9		က			yes	(c)	no	
x	D. R.	0/40/60	ಣ		ಣ			yes	(2)	no	
5 .	E	0/64/36	9		ಌ	slight luteal effect		yes	(2)	ou	
10	₹, €,		01		က		biphasic		(10)	ň	yes
11	E.	0/79/21	10		က	slight luteal effect		SOA.	(3)	ou	
<u>-1</u>	H	0/71/99	4	t~	ᢐ	not modified	monophasic	sov.	<u>13</u>	011	
13	A. M.	0/59/41	4	21	ın.	estrogenic effect		yes	3	00	
14	K. L.	0/64/36	4		io.	not modified		011		011	
12	Ľ.		10		ಸ್ತ			Nes.	(4)	00	
16	M. F.		10	14	1-		biphasic	yes	(<u>o</u>	no	yes
17	P. Z.	01/06/0	4	1.2	10	not modified		spotting	ing	no	
$\frac{\mathbf{x}}{\mathbf{x}}$	6. 7.	0/56/44	ाः	x	10	luteal effect cytolysis	monophasic	ves (5)	(c)	no	
2	L. A.		्रा	t~	10			bleec ing t	bleeding dur-	505	
00	× ×	0/66/34	4	*	10	luteal effect		r 2	(S)	ou	
- 5 1	A.M.		0.10	13	10		biphasic	.ves	Œ	no	ves

	ves	pregnancy ves	ves	yes
ou ou	no It	Ĕ	no	ou
(12) (6)	yes (4) bleeding during treatment	<u>©</u>	(+)	£ 6
sax sax	ves blee	r ves	83.	yes.
	biphasic	biphasic biphasic	biphasic	biphasic biphasic
eytolytic smear	not modified	luteal effect		luteal effect luteal effect
0 0 0	21 21	† †	50	8 8 8 8
13 16	==	12	1 0	6 91
ক ক গ	10 10	מו מו	+	÷1 4
$0/88/12 \\ 0/84/16 \\ 0/96/4$	0/98/2	0/70/30	eytolytic smear	do. 0/40/60
S. S. H. B. Y. E.	Y. E. L. A.	R. B. M. F.	Y. E.	Z. Y. D. R.
23 24 24	24 a 19 a	25 16 a	11	ล ส เว ช

* with ethinylestradiol

Table IV Ro 4-8347 in amenorrhea

	No., name	Diagnosis	Maturation Daily index be- dose fore treat- (mg) ment	Daily dose (mg)	Begins on day	Begins During on day days	Begins During Vaginal smear after on day days treatment	BBT after treatment	Bleeding after Ro 4-8347 (during days)	Side- Ovu- effects lation	Ovu- latior
	F. Y.	short term	0/83/17	2		4	not modified		* yes (4)	01	
٠ì	N. N.	short term	61/18/0	91		ာ၊			ves (4)	011	
**	B. E.	short term	0/95/5	10		ି ବ୍ୟ			. 93	011	
+	B. N.	short term	0/74/26	01		्रा	estrogenie effect		011	011	
10	۲. ٥.	short term	0/94/6	01		≎1	not modified		(4) 40%	011	
=	D. I.	short term	0/80/20	10		ଦା			ves (3)	011	
1~	r. S	short term	0/85/15	01		ণ				011	
x	G. ₹.	short term	01/06/0	10		ಣ	evtolysis		ou	110	
5.	X.	short term	0/85/15	ıc		₩			incomplete		
									abortion (5)		
10	D. A.	short term	0/85/15	01		1 10			ves (4)	no	
	F. Y.	secondary		01		কা			ves (5)	011	
÷1	L. M.	secondary	0/75/25	10		ಾ	luteal effect		ves (6)	00	
**	G. A.	secondary	0/82/18	10		ನ್	estrogenic effect		on	ou	
:3 a	G. A.	secondary	6/16/0	9		14	estrogenic effect		по	011	
+		secondary	0/90/10	+		īĊ	estrogenic effect		ou	110	
10	F. Y.	secondary	0/66/34	Ç1	15	14	luteal effect	biphasic	spotting during		ves.
	;	22	1		1	,			treatment		
:0	3. 0.	secondary	0/09/0	10	55	50 50	not modified	monophasic	no	110	

								SON.					
no	011	011	no	ou	ou	ou	ou	no	ou	no	ou	no	no
		s (7)			s (5)	s (6)	s (3)	s (3)	s (+)		s (2)	s (4)	s (1)
110	no	ve	no	nc	0.1.	A.	1.6	ves	1.6	no	ves	.v.	yes
								biphasic		monophasic			
not modified	not modified	luteal effect	not modified	not modified	slight luteal effect	not modified	luteal effect	luteal effect	estrogenic effect	not modified	slight luteal effect	estrogenic effect	estrogenic effect
57	2	373	က	က	ಣ	10	10	91	† 1	ţ	ΤŢ	14	50
	1:0						S	Ξ		<u>†</u>			
OI	2	9	2	φ	10	4	7	x	:9	10	9	9	9
6/16/0	0/98/2	0/80/20	0/84/16	0/88/12	0/80/20	0/90/10	0/62/38	0/61/39	0.86/14	01/06/0	0/82/18	0/11/23	
primary	primary	primary	primary	primary	primary	primary.	primary	primary	primary	primary	primary	primary	primary
K. L.	X.	S. C.	G. R.	C. R.	K. A.	K. A.	X. X.	Х. Н.	S. H.	A. R.	S. M.	M. L.	M. L.
_	٠ı	**	4	10	φ	ន ទ	1-	x.	os S	5.	2	=	Ξ

 * + progesterone 100 mg

The Ro 4-8347 induced ovulation also in cases with minimal estrogenic activity. However, the response to its administration was both unpredictable and non-recurrent. A rational approach to treatment with Ro 4-8347 will be possible only when the precise mechanism of its activity is made clear.

The relatively low pregnancy rate, 2 in 37 ovulatory cycles, was discouraging. This may be improved by a more repeated use of this retrosteroid. We have not seen any case of ovarian overstimulation syndrome following treatment with retrosteroid.

Summary

The retroprogestational agent Ro 4-8347 was given in 85 cases of amenorrhea and anovulation in various dose schedules.

In 33 cases of anovulatory cyclic menstruation Ro 4-8347 induced ovulation in 24 out of 44 cycles of treatment (56%). Of 25 cases with oligomenorrhea, ovulation was induced in 10 out of 31 cycles of treatment (30%) and of 17 cases of amenorrhea, 2 ovulatory cycles were obtained in 20 cycles of treatment. Only 2 patients of this series became pregnant following treatment.

The "long course" of treatment consisting in the administration of 2–6 mg daily for 10–20 days gave better results than the "short course" of 4–10 mg daily for 2–6 days.

No case of ovarian overstimulation has been observed following treatment, and other side-effects were minimal.

Authors' address: Prof. Dr. W. Z. Polishuk, Dr. A. Schechter, and Dr. T. Kozminski, Department of Obstetrics and Gynecology, Hadassah University Hospital, P.O. Box 499, Jerusalem (Israel).